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Research
In eukaryotes, more than 80% of intra­
cellular proteins are degraded through the 
ubiquitin/proteasome­dependent pathway 
(Ciechanover 1998; Dou and Li 1999; 
Goldberg 1995). The ubiquitin/  proteasome­ 
dependent pathway plays an essential role 
in antigen presentation, cellular aging,   
apoptosis, and other major cellular pro­
cesses. The cellular proteasome, commonly 
called 26S proteasome, is composed of two 
19S regu  la  tory particles and a 20S core par­
ticle. The latter is a multicatalytic threonine 
protease with at least three distinct catalytic 
activities: chymotrypsin (CT)­like (cleavage 
after hydrophobic residues mediated by the 
β5 subunit), trypsin­like (cleavage after basic 
residues by the β2 subunit), and peptidyl­
glutamyl peptide­hydrolyzing (PGPH)­like 
(cleavage after acidic residues by the β1 sub­
unit) (Goldberg 1995; Groll et al. 1997). 
Inhibition of proteasome CT­like activity 
by various compounds is associated with cell 
apoptosis (An et al. 1998; Lopes et al. 1997).
Since the 1960s, organotins, especially tri­
phenyltin (TPT) and tributyltin (TBT), have 
been extensively used as antifouling boat paints, 
polyvinyl chloride stabilizers, agricultural pesti­
cides, and industrial catalysts. Consequently, 
organotin contamination is found in various 
environmental media (Fent 1996). Because 
of their lipophilic property, organotins can 
be accumulated through the food chain and 
reach higher concentrations in top predators. 
For example, levels of organotins in stranded 
whales reached 1.0–1.1 mg/kg (Harino et al. 
2007) and in the liver of harbor porpoises 
reached 68–4,605 mg/kg (Strand et al. 2005). 
Organotin chemicals have also been found in 
the tissues of humans contaminated by organo­
tin insecticides or food (Kannan et al. 1999).
Exposure to TPT or TBT can also affect 
sex differentiation, resulting in masculinization 
of females or infertility in males (McAllister and 
Kime 2003; Smith 1996). TBT at low concen­
trations is toxic to cortical neurons by triggering 
glutamate excitotoxicity (Nakatsu et al. 2006). 
TBT also induces the differentiation of adipo­
cytes in vitro and increases adipose mass in 
vivo, perhaps through activation of the retinoid 
X receptor and the peroxisome­proliferator– 
activated receptor γ (Grun et al. 2006). Both 
TPT and TBT can interfere with the cytotoxic 
function of natural killer (NK) cells (Snoeij 
et al. 1987), associated with increased cancer 
incidence. However, the toxicologic mechanism 
for organotin compounds is not completely 
understood, and the essential cellular target of 
organotins has not been identified.
The authentic proteasome inhibitor clasto­
lactacystin β­lactone contains an electrophilic 
ester bond carbon that is responsible for its bio­
logical inhibition of the proteasome (Fenteany 
et al. 1995). We hypothesize that the electro­
philic tin (Sn) atom in organotins could also 
be attacked by the Oγ atom of the N­terminal 
threo  nine (Thr­1) of the proteasome β5 subunit, 
causing irreversible inhibition. This hypothe­
sis is supported by the present results from   
in silico docking, by in vitro proteasome activ­
ity assay using purified 20S proteasomes and 
human breast cancer MDA­MB­231 cells and 
human peripheral blood Jurkat T cells treated 
with TPT and other organotins, by analysis 
of CT­like activity, β5 proteasome subunit 
expression, and Sn levels in isolated proteasome 
complexes from the treated cells.
Materials and Methods
Materials. We obtained organotin compounds 
monophenyltin trichloride (MPT), diphenyltin 
dichloride (DPT), triphenyltin chloride (TPT), 
tetraphenyltin (TePT), monobutyltin trichlo­
ride (MBT), dibutyltin dichloride (DBT), 
tributyltin chloride (TBT), and tetrabutyltin 
(TeBT) from Acros Organics (Morris Plains, 
NJ, USA). A 50­mmol/L stock solution of 
each organotin [dissolved in methanol for all 
except TeBT and TePT; TeBT dissolved in 
dimethyl sulfoxide (DMSO), and TePT dis­
solved first in tetrahydrofuran and then diluted 
with an equal volume of DMSO], was stored 
at –20°C. Purified rabbit 20S proteasomes 
and fluorogenic peptide substrates Suc­LLVY­
AMC, Z­GGL­AMC (for CT­like activity), 
Z­LLE­AMC (for PGPH­like activity), and 
Z­ARR­AMC (for trypsin­like activity) as well 
as Ac­DEVD­AMC (for caspase­3/7 activity) 
were from Calbiochem Inc. (San Diego, CA, 
USA). Rabbit antibody to 20S proteasome 
subunit β5, agarose­immobilized mouse mono­
clonal antibody to the 20S proteasome sub­
unit α2 (HC3), and mouse antibody against 
human poly(ADP­ribose) polymerase (PARP) 
were purchased from BIOMOL International 
(Plymouth Meeting, PA, USA). Antibodies 
against Bax (B­9), p27 (F­8), ubiquitin 
(P4D1), actin (C­11), and IκB­α (C15) were 
from Santa Cruz Biotechnology, Inc. (Santa 
Cruz, CA, USA). The Apo­Direct Kit was 
from BD Biosciences Pharmingen (San Jose, 
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Ba c k g r o u n d: Because of the vital importance of the proteasome pathway, chemicals affecting pro-
teasome activity could disrupt essential cellular processes. Although the toxicity of organotins to both 
invertebrates and vertebrates is well known, the essential cellular target of organotins has not been well 
identified. We hypothesize that the proteasome is a molecular target of environmental toxic organotins.
oBjectives: Our goal was to test the above hypothesis by investigating whether organotins could 
inhibit the activity of purified and cellular proteasomes and, if so, the involved molecular mechanisms 
and downstream events.
re s u l t s: We found that some toxic organotins [e.g., triphenyltin (TPT)] can potently and prefer-
entially inhibit the chymotrypsin-like activity of purified 20S proteasomes and human breast cancer 
cellular 26S proteasomes. Direct binding of tin atoms to cellular proteasomes is responsible for the 
observed irreversible inhibition. Inhibition of cellular proteasomes by TPT in several human cell 
lines results in the accumulation of ubiquitinated proteins and natural proteasome target proteins, 
accompanied by induction of cell death.
co n c l u s i o n s: The proteasome is one of the molecular targets of environmental toxic organotins in 
human cells, and proteasome inhibition by organotins contributes to their cellular toxicity.
key w o r d s : cell death, molecular target, organotins, proteasome, proteasome inhibitors, TPT. 
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CA, USA), and agarose­immobilized aproti­
nin and Ultrafree­MC centrifugal filter unit 
[M0286; pore size, 5­kDa molecular­weight 
(MW) cutoff] were from Sigma­Aldrich (St. 
Louis, MO, USA).
Cell cultures, cell extract preparation, and 
Western blot analysis. We cultured human 
breast cancer MDA­MB­231 cells and human 
peripheral blood Jurkat T cells and prepared 
whole­cell extracts as previously described (An 
et al. 1998). Western blot analysis using the 
enhanced chemiluminescence reagent was per­
formed as previously described (An et al. 1998).
Proteasome activity assays using purified 
20S proteasomes in intact cells. We measured 
the inhibition of purified 20S proteasomal 
activity (An et al. 1998) and 26S proteasomal 
activity in living intact cells (Chen et al. 2005) 
as described previously.
Proteasome and caspase-3 activity assays 
using cell extracts. The prepared whole­cell 
extracts (10 µg per sample) from treated cells 
were incubated with the appropriate fluorogenic 
peptide substrates in 100 µL assay buffer at 
37°C for 2 hr. We measured the release of the 
7­amino­4­methylcoumarin (AMC) groups as 
previously described (An et al. 1998).
Trypan blue dye exclusion assay and ter-
minal deoxynucleotidyl transferase dUTP nick 
end-labeling (TUNEL) assay. We used the 
trypan blue dye exclusion assay to ascertain 
cell death in Jurkat T cells treated with TPT 
or TBT as described previously (Chen et al. 
2005). The TUNEL assay using TPT­treated 
cells was performed with an APO­Direct kit 
to determine the extent of DNA strand breaks 
measured by flow cytometry according to the 
manufacturer’s instructions (An et al. 1998; 
Chen et al. 2005).
Assay for interaction of TPT and purified 
20S proteasome. We incubated purified rab­
bit 20S proteasomes (4 µg per reaction) with 
10 µmol/L TPT or the control solvent metha­
nol in 400 µL Tris­HCl buffer (25 mmol/L, 
pH 7.5) overnight at 4°C. The reaction mix­
ture was then transferred to the insert cup of 
Ultrafree­MC centrifugal filter unit (MW cut­
off, 5 kDa), which had been prewashed with 
400 µL 1% bovine serum albumin,1% sucrose 
solution to minimize proteasome binding to the 
unit, and the mixture centrifuged at 7,000 rpm 
for 1.5 hr at 4°C, which resulted in about 80 µL 
of the proteasome preparation in the insert cup. 
Then 320 µL Tris­HCl buffer was added to the 
insert cup containing the proteasome prepa­
ration, followed by centrifugation again. This 
wash–filtration procedure was repeated four 
times to remove free TPT. The proteasome 
preparation in the insert cup was diluted to 100 
µL with the Tris­HCl buffer and transferred to 
a storage tube. The insert cup was then washed 
with 50 µL Tris­HCl buffer and combined with 
the proteasome fraction. We used the prepared 
proteasome fraction for the proteasome activity 
and Western blot assays.
Assay for interaction of TPT and cellular 
26S proteasome. We treated MDA­MB­231 
cells with 10 µmol/L TPT or control solvent 
methanol for 2 hr, followed by preparation 
of whole­cell extracts and the 26S proteasome 
immunoprecipitates. In brief, 100 µL agarose 
beads immobilized with mouse monoclonal 
antibody to the 20S proteasome subunit α2, 
or agarose beads immobilized with aprotinin 
(as a nonspecific binding control), were equili­
brated with 1 mL buffer A (Tris­HCl buffer, 
25 mmol/L, pH 7.5) and then incubated with 
100 µL of the prepared cell extracts (~ 800 µg 
protein per preparation) overnight at 4°C 
in 700 µL buffer A. The reaction mixtures 
were centrifuged at 3,000 rpm for 1 min, the 
supernatants were removed, and the affinity 
matrixes were washed three times with 1 mL 
buffer A. The mixtures were resuspended with 
400 µL buffer A and separated into two ali­
quots (200 µL each). One aliquot was diluted 
to 400 µL and incubated with Suc­LLVY­
AMC (40 µmol/L) fluorogenic substrate at 
room temperature for 4 hr. After centrifugation 
at 3,000 rpm for 1 min, the supernatant was 
transferred to a 96­well plate for measurement 
of proteasome activity; the affinity matrix was 
resuspended with 100 µL 2× sodium dodecyl 
sulfate sample buffer, followed by Western blot 
analysis using proteasome β5 antibody. Another 
aliquot (200 µL) of the prepared proteasome 
immunoprecipitates was digested with an equal 
volume of 6 mol/L HCl for determination of 
the total Sn by inductively coupled plasma–
mass spectroscopy (ICP­MS).
ICP-MS analysis of Sn bound to proteasome. 
We determined total Sn levels in the prepared 
proteasome complexes with an Agilent 7500ce 
ICP­MS (Agilent Technologies, Santa Clara, 
CA, USA). The operating conditions were as 
follows: radiofrequency power, 1,240 W; Argon 
plasma gas (15 L/min), carrier gas (0.8 L/min), 
and makeup gas (0.27 L/min); sampling depth, 
8.5 mmol/L; operation mode, shield torch; 
acquired mass, 118; points/mass, 3.
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Figure 1. Inhibition of purified 20S proteasomes by organotins. Try, trypsin. Potency of phenyltins (A) and 
butyltins (B) to inhibit CT-like activity of purified 20S rabbit proteasomes. (C) TPT preferably inhibits CT-like 
activity of purified 20S rabbit proteasome. (D and E) Purified 20S proteasomes (4 µg) were incubated with 
10 µmol/L of TPT or the solvent methanol (Sol). After removing the unbound TPT from the proteasomes in 
an Ultrafree-MC centrifugal filter unit (MW cutoff, 5 kDa), the proteasome preparations were measured for 
CT-like activity (D) and β5 subunit levels in Western blotting (E). (F) TPT at 10 µmol/L inhibited proteasomal 
CT-like activity in a time-dependent manner. Data are mean ± SD from three experiments.
**p < 0.01. The proteasome is a molecular target of organotins
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In silico models for TPT binding to protea-
some β5 subunit. Because 99% of TPT is 
present as the neutral hydroxyl­complex form 
(TPT­OH) in physiologic conditions (pH 7.5) 
(White and Tobin 2004), the chemical struc­
ture of TPT was selected as (C6H5)3SnOH 
for docking studies. The crystal structure of the 
proteasome β5 subunit, the docking param­
eters, docking methods, and output analysis 
methods were the same as described previously 
(Smith et al. 2004). In brief, we first refined 
the molecule by performing an optimized 
geometry calculation saved in Protein Data 
Bank (PDB) files using the conversion filters 
in CAChe software (v 6.1) (Fujitsu America 
Inc., Beaverton, OR, USA). The output PDB 
files were imported into AutoDock 3.0 soft­
ware (The Scripps Research Institute 2008) for 
the in silico binding analysis to the proteasome 
β5 subunit. We chose the crystal structure 
of the proteasome β5 subunit of the eukary­
otic yeast 20S proteasome (PDB reference 
no. 1JD2; RCSB Protein Data Bank 2008), 
which is similar to human 20S proteasome 
(Smith et al. 2004). We defined the Sn atom 
of TPT as a rigid atom and limited the dock­
ing space to a 20 × 20 × 20 Å box centered 
on the β5­catalytic N­terminal threonine that 
was prepared as an energy­scoring grid. The 
output from AutoDock was used for docking 
model studies with PyMOL software (Smith 
et al. 2004).
Results
Inhibition of purified 20S proteasomes by 
organotins. We hypothesized that the pro­
teasome is a major target of organotins. To 
test this hypothesis, we first investigated the 
inhibition potency of phenyltins and butyl­
tins to purified 20S rabbit proteasomal activ­
ity. Among all the phenyltins tested (MPT, 
DPT, TPT, and TePT), TPT was the most 
potent inhibitor against proteasomal CT­like 
activity, with a half­maximal inhibitory con­
centration (IC50) of 3.5 µmol/L (Figure 1A). 
At 25 µmol/L, TPT and DPT caused 95% 
and 29% inhibition, respectively, whereas 
MPT and TePT had 15% or less inhibition 
(Figure 1A). When we tested butyltins with 
the purified 20S proteasome, we found a simi­
lar order of the CT­like­inhibitory activity: 
TBT (IC50 = 15.6 µmol/L) > DBT > MBT, 
TeBT (Figure 1B).
To investigate whether TPT specifically 
inhibits proteasomal CT­like activity, we 
examined its effects on the PGPH­like and 
trypsin­like activities of purified 20S protea­
somes. At 10 µmol/L, TPT inhibited CT­like 
and PGPH­like activity of the purified 20S 
proteasomes by 79% and 44%, respectively, 
but had no inhibitory effect against trypsin­
like activity (Figure 1C). Similarly, TBT had 
much less inhibitory effect on PGPH­like 
and trypsin­like activities of purified 20S 
proteasomes (data not shown). Therefore, it 
appears that organotins such as TPT and TBT 
preferentially inhibit proteasomal CT­like 
activity over other activities.
To further investigate the nature of TPT­
mediated proteasome inhibition, we incu­
bated the purified 20S proteasomes overnight 
at 4°C with either 10 µmol/L of TPT or 
control solvent. CT­like activity assays using 
an aliquot of each preparation indicated 
that TPT inhibited proteasome activity by 
57% under these experimental conditions 
(Figure 1D, “before spin”). Most of the reac­
tion mixtures were then washed several times 
with an Ultrafree­MC centrifugal filter unit 
(MW cutoff, 5 kDa) to remove small mole­
cules, including free TPT. The proteasomal 
activity assay shows that repeated washing 
and filtration of the TPT­proteasome mixture 
did not change the outcome: TPT still caused 
51% inhibition of proteasomal CT­like 
activity (Figure 1D, “after spin”). The lower 
level of the proteasomal activity detected in 
the TPT–20S proteasome mixture was not 
due to decreased levels of 20S proteasomes 
because an equal level of β5 subunit protein 
was detected by Western blotting in the two 
preparations (Figure 1E). This result indicates 
that TPT is either a tight­binding or an irre­
versible inhibitor of the proteasome.
Kinetics of proteasome inhibition by TPT. 
Our data (Figure 1F) indicate that TPT 
inhibited proteasomal CT­like activity in a 
time­dependent manner: by 23%, 35%, 64%, 
and 76%, respectively, after 15, 30, 60, and 
150 min. Because the observed proteasome­ 
inhibition kinetics are characteristic for a 
mechanism­based inhibitor (Vicentini et al. 
2001), we suggest that the TPT­mediated 
proteasome inhibition is irreversible.
Computational study of TPT–proteasome 
β5 interaction. In order to build a model 
to explain how TPT inhibits proteasomal 
CT­like activity, we performed automated 
docking studies. The docking results indi­
cate that TPT has a major docking mode that 
repeated for 47 of 100 runs (47% probabil­
ity). The distance from the Sn atom to the Oγ 
on Thr­1 was 2.97 Å, and one of the phenyl 
rings of TPT was located within the S1 hydro­
phobic pocket of β5 subunit (Figure 2A). It 
is well documented that the Thr­1 Oγ atom 
could be activated by Thr­1 N directly or via 
a neighboring water molecule, and reacts with 
Figure 2. Docking studies for the interaction of TPT and the proteasome β5 subunit. (A) The docking model 
of TPT-OH with a tetrahedral conformation in the proteasomal β5 CT site; TPT-OH is represented by a stick 
structure. (B) A hypothetical mechanism for the interaction between TPT-OH and the β5 Thr-1 residue. 
(C) Comparison of TPT-OH with tetrahedral conformation (white) and trigonal bipyramidal conformation 
(pink) in the β5 site. The three phenyl rings, one OH legend, and Oγ on Thr-1 form the trigonal bi  pyramidal 
conformation; the Sn on TPT and Oγ of Thr-1 are shown as spheres. (D) The hydrophobic interaction 
between the phenyl ring of TPT and the hydrophobic side chains in the S1 pocket. The mesh represents 
the surface of the S1 pocket.
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the electrophilic groups of inhibitors (Groll 
et al. 1997). Because the Sn atom in TPT 
was close to the Thr­1 Oγ atom, we hypothe­
sized that the Thr­1 Oγ atom might perform a 
nucleophilic attack on the Sn atom and form 
a coordinate bond (Figure 2B). It has been 
reported that with the attack of a nucleophilic 
ligand, the Cl ligand on the Sn atom of TBT 
or TPT could be replaced by the nucleophilic 
ligand, or the hybridization state of the Sn 
atom could change from sp3 to dzsp3, which 
allows the Sn atom to form a new coordinate 
bond with the nucleophilic ligand (Burda 
et al. 2002).
After the nucleophilic attack by Thr­1 Oγ, 
the TPT–Thr­1 complex could be present in 
two possible conformations: tetra  hedral (Sn 
in sp3 hybridization) and trigonal bipyrami­
dal (Sn in dzsp3 hybridization). To deter­
mine whether the hybrid orbit orientation 
of Sn atom and the three­dimension space 
around Thr­1 Oγ could allow the formation 
of any of these conformations, we performed 
further docking studies. To mimic the coor­
dinate complex of TPT–Thr­1, a threonine 
amide group was used as one of the ligands 
for Sn. The complex structure was refined 
by performing an optimized geometry cal­
culation in MOPAC using PM5 parameters 
in the CAChe software. After optimization 
of the geometry, the threonine amide ligand 
was removed and the remaining structure 
was docked into the proteasome β5 subunit 
with AutoDock 3.0 software. The docked 
results indicate that TPT has one major trigo­
nal bipyramidal conformation (Sn in a five­
coordinate form; Figure 2C) that allows the 
formation of a coordinate bond. In contrast, 
the tetrahedral conformation (Sn in a four 
coordinate) does not give an orientation that 
allows the Sn and Thr­1 Oγ to form a coordi­
nate bond (data not shown).
In the major trigonal bipyramidal confor­
mation mode that repeated in 63 of 100 runs 
(63% probability), the OH ligand and two 
phenyl rings of TPT were on the equatorial 
orbit, whereas the third phenyl ring of TPT 
and the Thr­1 Oγ of β5 was on the axis orbit 
(Figure 2C). The distance between Sn and 
Oγ was 2.81 Å, and the line between Sn and 
Oγ was basically on the axis orbit orientation 
(Figure 2C), supporting that a coordinate 
bond could form between Sn and Oγ. Also, 
one of the TPT hydrophobic phenyl ligands 
was oriented in the S1 pocket of β5 subunit 
(Figure 2D). The hydrophobic portion of the 
aromatic phenyl ring is oriented in the mid­
dle of the S1 pocket, with distances of 4.21 
and 3.48 Å, respectively, to the side chains of 
Ala­49 and Lys­33 (Figure 2D). In addition, 
the sidewalls of the S1 pocket, which pos­
sibly interact with TPT hydrophobically, are 
created by Met­45, Ala­20, and Val­31 with 
distances of 3.26, 3.43, and 3.52 Å, respec­
tively (Figure 2D). We also found that the 
distance between the amide hydrogen of Thr­
21 and the oxygen on the hydroxide ligand of 
TPT is only 2.00 Å (Figure 2C), indicating 
the possible formation of a hydrogen bond. 
Therefore, the irreversible inhibition nature 
of TPT is supported by the docking results, 
the possible formation of a coordinate bond 
between Sn of TPT and Thr­1 Oγ, blockage 
of the S1 pocket by a TPT phenyl ring, the 
possible hydrophobic inter  actions, and hydro­
gen bond formation.
Organotins cause cellular proteasome inhi-
bition and cell death. To investigate whether 
the organotins could inhibit cellu  lar protea­
somal activity in intact cells, we chose human 
breast cancer MDA­MB­231 cells as a work­
ing model. The cells were plated in a 96­well 
plate and then treated with 10 µmol/L of each 
butyltin or phenyltin compound, SnCl4 (an 
inorganic tin as a comparison), or solvent (as a 
control) for 4 hr and the proteasomal CT­like 
activity was measured. We found that TPT 
was most potent among all the organotins 
tested and caused 63% proteasome inhibition 
under the experimental condition, whereas 
DPT, MPT, and TePT inhibited the pro­
teasomal CT­like activity by 35%, 24%, and 
11%, respectively (Figure 3A). Therefore, the 
rank of potency to inhibit cellular protea­
some activity by organic phenyltins was: TPT 
> DPT > MPT > TePT, consistent with that 
of these phenyltins to inhibit the purified 
20S proteasomal CT­like activity (compare 
Figures 3A and 1A).
Similarly, butyltins TBT, DBT, MBT, 
and TeBT inhibited the cellular proteasomal 
CT­like activity by 60%, 27%, 21%, and 
10%, respectively (Figure 3A). The rank of 
potency in butyltins was TBT > DBT > MBT 
> TeBT, again similar to that of their inhib­
itory activities to the purified proteasomes 
(Figure 1B).
To verify the cellular proteasome­inhibi­
tory ability of the organotins, MDA­MB­231 
cells were grown on 100­mm dishes and then 
treated under the same condition (10 µmol/L 
of each butyltin or phenyltin compound for 
4 hr). After the treatment, cells were col­
lected and the cell extracts were prepared for 
analysis of proteasome inhibition by measur­
ing accumulation of ubiquitinated proteins. 
We detected accumulation of ubiquitinated 
proteins mainly after treatment with TPT or 
Figure 3. The proteasome-inhibitory and cell-death–inducing activities of organotins in MDA-MB-231 cells. 
Try, trypsin. (A) Proteasomal CT-like activity measured in intact MDA-MB-231 cells treated with the solvent 
methanol (Sol), inorganic Sn salt (SnCl4), or organotins (butyltins and phenyltins) at 10 µmol/L for 3 hr, fol-
lowed by 1 hr additional incubation with 40 μmol/L of Z-CGL-AMC. (B) Western blot assay of ubiquitinated 
(Ub-)proteins, Ub-IκB-α, PARP, and Bax proteins in extracts from MDA-MB-231 cells treated with 10 µmol/L 
of organotins, SnCl4, or control for 4 hr. (C) Preferential inhibition of CT-like activity of cellular proteasome 
by TPT. Data are mean ± SD of three experiments.
*p < 0.05. **p < 0.01.
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TBT (Figure 3B). Other organotins had much 
less effect, whereas SnCl4 failed to increase 
the level of ubiquitinated proteins, compared 
with the solvent control (Figure 3B).
We have reported a ubiquitinated form 
of IκB­α protein with MW of about 56 
kDa (Chen et al. 2007). A similar p56 band 
appeared after treatment of TPT or TBT, as 
detected by the specific antibody to IκB­α 
(Figure 3B, Ub­IκBα). In comparison, other 
organotins and SnCl4 showed no effect on 
accumulating the ubiquitinated IκBα protein 
(Figure 3B).
To investigate whether proteasomal 
inhibition by organotins is associated with 
cell death induction, we investigated both 
morphologic changes and PARP cleavage. 
Morphologic changes (shrinking, blebbing) 
were observed mainly in the MDA­MB­231 
cells treated with TPT or TBT (data not 
shown, but see Figure 4C). Consistently, 
treatment with TPT or TBT caused the 
disappearance of the intact PARP protein 
(116 kDa), associated with production of a 
cleaved PARP fragment (Figure 3B). In con­
trast, other organotins were weaker cell death 
inducers and generated mild morphologic 
changes (data not shown). Only DPT treat­
ment caused a low level of PARP cleavage; 
other organotins and inorganic SnCl4 had no 
effect (Figure 3B).
We and others have shown that, associ­
ated with apoptotic commitment, Bax protein 
(p21/Bax) could be cleaved by calpain, pro­
ducing a p18/Bax fragment that then forms 
a homodimer p36/Bax (Gao and Dou 2000; 
Wood and Newcomb 2000). Treatment of 
MDA­MB­231 cells with TPT and TBT also 
caused an increase in levels of p36/Bax, asso­
ciated with decreased levels of p21/p18/Bax 
(Figure 3B). In contrast, other organotins had 
much less effect (Figure 3B).
We then examined whether TPT and 
TBT could specifically inhibit the pro­
teasomal CT­like activity in intact cells. 
MDA­MB­231 cells were treated with TPT 
or TBT at indicated concentrations for 12 
hr, followed by measuring the three pro­
teasomal activities in cell lysates prepared. 
At 2.5 µmol/L, TPT inhibited the CT­like, 
PGPH­like, and trypsin­like activities of the 
cellular proteasomes by 72%, 33%, and 3%, 
respectively (Figure 3C). Similarly, TBT also 
preferentially inhibited the CT­like activity 
over two other activities of the cellular protea­
somes (data not shown). This result confirms 
that both TPT and TBT selectively inhibit 
proteasomal CT­like activity.
A 6­hr treatment of MDA­MB­231 cells 
with TPT at 1.0, 2.5, and 5.0 µmol/L also 
caused a dose­dependent inhibition (by 30%, 
40%, and 58%, respectively) of the protea­
somal CT­like activity (Figure 4A). Similarly, 
treatment for 6 hr with TBT at 1.0, 2.5, and 
5.0 µmol/L inhibited 8%, 39%, and 46% 
of the cellular proteasomal CT­like activity, 
respectively (Figure 4A). Consistent with that, 
we detected increased levels of polyubiquit­
inated proteins, IκBα, and the ubiquitinated 
form of IκBα in a dose­dependent manner 
in the cells treated with TPT (Figure 4B) 
and TBT (data not shown), compared with 
the cells treated with inorganic SnCl4 or sol­
vent. For example, levels of unmodified IκBα 
protein were increased by TPT at 1 and 2.5 
µmol/L, and the ubiquitinated IκBα protein 
was accumulated by TPT at 2.5 µmol/L and 
was further increased by TPT at 5 µmol/L, 
associated with a decreased level of unmodi­
fied IκBα protein (Figure 4B). Furthermore, 
cell death also occurred in a dose­dependent 
fashion in the cells treated with TPT or TBT, 
as supported by cellular morphologic changes 
(Figure 4C) and PARP cleavage into p85 and 
p65 fragments (Figure 4B). We also observed 
cleavage of p21/Bax into p18/Bax and accu­
mulation of p36/Bax in the cells treated with 
TPT (Figure 4B). These results demonstrate 
that TPT and TBT can inhibit cellular protea­
somal CT­like activity, resulting in activation 
of cell­death–associated proteases. However, 
treatment with either TPT (Figure 4D) or 
Figure 4. Dose effects of TPT and TBT on proteasome inhibition and cell death induction in MDA-MB-231 
cells. Abbreviations: PI, propidium idodide; TdT FITC, terminal deoxynucleotidyl transferase fluorescein iso-
thiocyanate. (A) Proteasomal CT-like activity measured in MDA-MB-231 cells exposed to either methanol 
(Sol), SnCl4 at 5 µmol/L, TPT, or TBT at the indicated concentrations for 6 hr (data are mean ± SD of three 
experiments). (B) Western blot assays of ubiquitinated proteins, ubiquitinated IκB-α (Ub-IκB-α), PARP, 
and Bax proteins levels in cell extracts. (C) Morphologic changes (100× magnifications; scale bar, 150 µm.   
(D) TUNEL assay.
*p < 0.05. ** p < 0.01. 
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TBT (data not shown) at all the tested con­
centrations did not cause DNA strand breaks, 
as evidenced by negativity of TUNEL assay, 
suggesting that organotin­induced cell death 
does not involve DNA damage.
Kinetic studies of proteasome inhibition by 
TPT. To determine whether proteasome inhi­
bition or cell death is induced first by organ­
otins, we treated MDA­MB­231 cells with 
5 µmol/L of TPT for different time points, 
followed by measurement of proteasome inhi­
bition and cell death. The proteasome inhibi­
tion by TPT started as early as 30 min, as 
shown by 35% inhibition of the proteasomal 
CT­like activity and accumulation of ubiquit­
inated proteins (Figure 5A,B). By 1 hr, protea­
some activity decreased by 40% (Figure 5A) 
and levels of ubiquitinated proteins were fur­
ther increased (Figure 5B). The ubiquitinated 
proteins accumulated until the last time point 
(16 hr, Figure 5B). Although levels of unmod­
ified IκBα protein increased between 1 and 
2 hr, that of ubiquitinated IκBα protein accu­
mulated between 6 and 16 hr (Figure 5B). 
Importantly, cell death was not observed 
before 2 hr treatment with TPT, as shown 
by lack of caspase­3/7 activation (Figure 5A), 
PARP cleavage (Figure 5B), and cellular mor­
phologic changes (data not shown). Only 
between 2 hr and 6 hr treatment with TPT 
was caspase­3/7 activity increased (by 3­ to 
4­fold; Figure 5A) and strong PARP cleavage 
bands detected (Figure 5B). Calpain activation 
was also found after 2 hr treatment, as shown 
by the increased levels of p65/PARP (Pink 
et al. 2000) and p18/Bax, as well as p36/Bax 
(Figure 5B). These results suggest that protea­
some inhibition by TPT contributes to cell 
death induction.
Organotins inhibit proteasome activity in 
multiple human cell lines. One of the in vivo 
targets of organotins is the immune system. 
We therefore investigated whether organo­
tins can inhibit proteasome activity in human 
peripheral blood Jurkat T cells. Jurkat cells 
were treated with TBT and TPT at concen­
trations ranging from 0.01 to 2.5 µmol/L for 
8 hr, followed by measurement of the pro­
teasomal CT­like activity, cell death, and 
TUNEL assays. TPT inhibited 14%, 33%, 
58%, 79%, and 91% of proteasomal CT­like 
activity at concentrations of 0.01, 0.1, 0.5, 1, 
and 2.5 µmol/L, respectively, and TBT showed 
similar dose­dependent inhibition (Figure 6A). 
Again, SnCl4 at 5 µM had no inhibitory effect 
(Figure 6A). Proteasome inhibition in Jurkat 
cells treated with TPT and TBT was accom­
panied with dose­dependent cell death: TPT 
induced 12% and 77% cell death at 0.01 and 
2.5 µmol/L, respectively, whereas TBT 
induced 10% and 71% cell death at 0.01 and 
2.5 µmol/L (Figure 6B). Again, SnCl4 at 5 µM 
had no such effect (Figure 6A,B). TUNEL 
assay showed again that both TBT and TPT 
did not cause DNA strand breaks in Jurkat T 
cells (Figure 6C and data not shown), confirm­
ing that organotin­induced cell death is DNA–
damage independent. Similar results were also 
found in human prostate cancer LNCaP cells 
and human normal, nontransformed YT natu­
ral killer cells (data not shown).
Direct binding of TPT to the cellular 
proteasome. To provide direct evidence for 
binding of TPT to cellular proteasome, we 
treated MDA­MB­231 cells with 10 µmol/L 
TPT or solvent for 2 hr, followed by prepar­
ing the proteasome immunoprecipitates using 
an antibody to the proteasomal α2 subunit. 
Aliquots of the prepared proteasome immu­
noprecipitates were used for measuring the 
associated proteasomal activity (Figure 7A), β5 
subunit protein (Figure 7B), and the bound 
total Sn level (Figure 7C). A lower level of 
CT­like activity was found in the protea­
some complexes prepared from the cells 
treated with TPT, compared with the con­
trol (Figure 7A), confirming the strong pro­
teasome­inhibitory activity of TPT in cells. 
Equal protein levels of β5 subunit were found 
in the aliquots of the two proteasome immuno­ 
precipitate preparations (Figure 7B), indicat­
ing that the decreased proteasome activity in 
TPT­treated sample preparation is not due 
to loss of the proteasome complex. Indeed, 
about 2.7 pM total Sn was found only in the 
aliquot of the proteasome complexes prepared 
from cells treated with TPT and not in the 
control (Figure 7C). As a nonspecific binding 
control, no Sn was detected in aprotinin com­
plexes prepared from the above TPT­treated 
cells (Figure 7C).
Because TPT is relatively stable and can be 
slowly degraded to DPT, MPT, and inorganic 
Figure 6. Dosage effects of TPT and TBT on proteasome inhibition and cell death in Jurkat T cells. Jurkat 
T cells were exposed to either methanol (Sol), SnCl4 at 5 µmol/L, or TPT and TBT at the indicated con-
centrations for 8 hr. (A) Measured proteasome CT-like activity. (B) Percentage of cell death measured by 
trypan blue assay. (C) TUNEL assay. Data are means ± SD of three experiments.
*p < 0.05. **p < 0.01
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Figure 5. Kinetic studies on proteasome inhibition 
and cell death induction by TPT. (A) Exponentially 
grown MDA-MB-231 cells (0 hr) were exposed to 
5 µmol/L of TPT for the indicated hr, and proteasome 
CT-like (triangles) and caspase-3 (squares) activi-
ties were measured. Data are mean ± SD of three 
experiments. (B) Western blot analysis of samples 
from the same experiment using specific anti  bodies 
to ubiquitin, IκB-α, PARP, Bax, and β-actin.
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tins only by human cytochrome P450 iso­
forms (Ohhira et al. 2006), and because only 
TPT at 10 µmol/L could cause 50% inhibi­
tion of proteasomal activity (Figures 3A, 4A), 
we believe that most cellular Sn detected in 
the proteasome immunoprecipitates under 
our experimental condition (within 2 hr treat­
ment) should be TPT. Therefore, we conclude 
that the detected Sn represents TPT binding 
to the proteasome, which is responsible for 
the decreased proteasomal CT­like activity in 
the cells. These data strongly suggest that the 
proteasome is a direct cellular target of TPT.
Discussion
In the present study, we have provided several 
lines of evidence that suggest the proteasome 
as an important cellular target of environmen­
tal toxic organotins. We have shown that TPT 
binds the proteasomal CT β5 site by in silico 
docking analysis (Figure 2) and that TPT 
potently and preferentially inhibits CT­like 
activity of purified 20S proteasomes (Figure 1) 
and cellular 26S proteasomes (Figures 3–6) in 
an irreversible manner. We have also shown 
direct binding of TPT to the proteasome in 
cells (Figure 7).
We found that phenyltins could inhibit 
both purified (Figure 1A) and cellular pro­
teasomal CT­like activity (Figure 3A). The 
rank of inhibition potency was TPT > DPT 
> MPT, TePT. The various proteasome­
inhibitory potencies of these phenyltins were 
roughly associated with their abilities to 
increase ubiquitinated proteins and the ubiq­
uitinated form of IκB­α (Figure 3B). Similar 
conclusions can be drawn for the butyltins.
It has been well documented that the 
interaction and modification of the OH group 
on Thr­1 of proteasome β5 subunit are criti­
cal for the irreversible inhibition of CT­like 
activity (Fenteany et al. 1995). Results from 
our docking study suggest that Sn present in 
TPT might coordinately interact with the Oγ 
atom of Thr­1 of the proteasome β5 subunit 
(Figure 2). This hypothesis was supported 
by our experimental data that TPT irrevers­
ibly inhibited proteasomal CT­like activity 
(Figure 1). We therefore proposed a mecha­
nism for the interaction between TPT and 
proteasome β5 subunit in which the Sn atom 
in TPT could be attacked nucleophilically by 
Thr­1 Oγ, and the hybridization state of Sn 
could then change from sp3 to dzsp3, which 
allows the Sn to form a new coordinate bond 
with Thr­1 Oγ (Figure 2). During this pro­
cess, the positions of phenyl groups might 
need only a minor change from their original 
tetrahedral conformation (Figure 2C).
The following arguments are consistent 
with the idea that TPT­mediated protea­
some inhibition is functional and responsi­
ble for the observed cell death. First, when 
MDA­MB­231 cells were treated with TPT 
(or TBT), proteasome inhibition, calpain or 
caspase activation, and cell death induction 
were increased in both a dose­ and time­
dependent manner (Figures 3–5). Second, 
proteasome inhibition occurred before cell 
death (Figure 5), as demonstrated by multiple 
assays. Finally, similar data were obtained in 
human peripheral blood Jurkat T cells and 
other cell lines (Figure 6 and data not shown).
The most significant finding of the pres­
ent study is the detection of Sn in the iso­
lated proteasome complexes from the cells 
treated with TPT (Figure 7). We found no 
inter  action of Sn and proteasomes in pro­
teasome immunoprecipitates we prepared 
from the cells treated with the control solvent 
(Figure 7C) or in aprotinin (a serine protease 
inhibitor) complexes we prepared from the 
cells treated with TPT (Figure 7C), demon­
strating a specific interaction. Based on the 
proteasome inhibition potency of phenyltins 
and the known pharmacokinetics of TPT 
metallization, we conclude that the detected 
Sn in the isolated proteasome complexes rep­
resents the bound TPT. These data strongly 
suggest that TPT directly binds to the cellular 
proteasomal β5 subunit and inhibits CT­like 
activity in cells.
We found that TPT (and TBT) prefer­
ably inhibited CT­like activity of purified 20S 
proteasomes (Figure 1C) and cellular protea­
somes (Figure 3C), suggesting that β5 sub­
unit is a specific target for organotins. This 
finding is significant because inhibition of the 
proteasomal β5 CT­like activity is associated 
with cell apoptosis (An et al. 1998; Lopes et al. 
1997). Indeed, cell death occurred after TPT 
or TBT treatment. It appears that organotins 
induce at least some type of apoptosis because 
caspase­3 activation and p85 PARP cleav­
age fragment were observed (Figures 4, 5). 
However, cell death seems to not involve 
DNA damage because TUNEL assays showed 
negative results (Figures 4, 6). Because calpain 
is associated with necrosis and is activated by 
TPT and TBT, we also suspected occurrence 
of necrosis under our experimental conditions. 
Taken together, we conclude that organo­
tins can induce necrosis and some caspase­ 
dependent, DNA­damage–independent cell 
death. Finally, because organotins have similar 
effect on LNCaP cells (containing wild­type 
p53 gene), MDA­MB­231 (mutant p53) cells, 
and Jurkat T cells (mutant p53), we suggest 
that organotins kill cells via a p53­indepen­
dent pathway. This hypothesis is consistent 
with our previous report about proteasome 
inhibitors inducing tumor cell death in a p53­
independent manner (An et al. 1998).
Our present findings may also provide an 
explanation for some previous observations. 
TPT and TBT have been reported to induce 
apoptosis in various cell systems (Mundy and 
Freudenrich 2006; Stridh et al. 1999), and 
some potential targets of organotins include 
NF­κB (Marinovich et al. 1996) and Bax 
(Zhu et al. 2007). Our results suggest that 
these previous observations might be down­
stream of proteasome inhibition because deg­
radation of both IκB and Bax is regulated by 
the proteasome pathway (Dou and Li 1999; 
Li and Dou 2000). Furthermore, exposure 
to TPT or TBT has been shown to induce 
imposex, a pseudohermaphroditic condition, 
in female sea animals (Smith 1996). Because 
cytochrome P450 aromatase is the critical 
enzyme to catalyze the conversion of andro­
gen to 17β­estradiol in eukaryote cells, inhi­
bition of aromatase activity by TBT or TPT 
was often assumed to be responsible for the 
development of masculinized organs in female 
animals (Spooner et al. 1991). We suggest 
that inhibition of aromatase activity observed 
in organotin­exposed animals is due to inhibi­
tion of the proteasomes because proteasome 
inhibition causes up­regulation of the tran­
scription factors USF1/2 (upstream stimula­
tory factors 1 and 2), which in turn suppress 
transcription of the hCYP19/aromatase gene 
(Jiang and Mendelson 2005).
Figure 7. Direct interaction of TPT and the cellu-
lar proteasome. The 26S proteasome immunopre-
cipitates were prepared from MDA-MB-231 cells 
treated with 10 µmol/L TPT or methanol for 2 hr. The 
whole-cell extracts were immunoprecipitated with 
agarose beads conjugated with 20S proteasome 
subunit α2 antibody. Abbreviations: Sol, solvent; 
Supern, supernatant. (A) Associated proteasomal 
CT-like activity; (B) Proteasomal β5 protein level; 
(C) Total Sn level measured by ICP-MS. Aprotinin 
immunocomplexes prepared from the cells treated 
with TPT were used as a nonspecific TPT binding 
control. Data are mean ±SD of three experiments. 
**p < 0.01.
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In summary, the results from our present 
study strongly suggest that the proteasome is 
one of the molecular targets of environmental 
toxic organotins in human cells. The connec­
tion of organotin exposure to cellular protea­
some inhibition provides a novel mechanism 
for environmental influences on human or 
animal health.
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